The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A highly reproducible rotenone model of Parkinson's disease
Open accessAbstract
The systemic rotenone model of Parkinson's disease (PD) accurately replicates many aspects of the pathology of human PD and has provided insights into the pathogenesis of PD. The major limitation of the rotenone model has been its variability, both in terms of the percentage of animals that develop a clear-cut nigrostriatal lesion and the extent of that lesion. The goal here was to develop an improved and highly reproducible rotenone model of PD. In these studies, male Lewis rats in three age groups (3, 7 or 12-14 months) were administered rotenone (2.75 or 3.0 mg/kg/day) in a specialized vehicle by daily intraperitoneal injection. All rotenone-treated animals developed bradykinesia, postural instability, and/or rigidity, which were reversed by apomorphine, consistent with a lesion of the nigrostriatal dopamine system. Animals were sacrificed when the PD phenotype became debilitating. Rotenone treatment caused a 45% loss of tyrosine hydroxylase-positive substantia nigra neurons and a commensurate loss of striatal dopamine. Additionally, in rotenone-treated animals, α-synuclein and poly-ubiquitin positive aggregates were observed in dopamine neurons of the substantia nigra. In summary, this version of the rotenone model is highly reproducible and may provide an excellent tool to test new neuroprotective strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Self-citationAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11001.x · Cited by 1,290
Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
Deumens, R., Blokland, A., & Prickaerts, J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7891 · Cited by 758
Sherer, T. B., Kim, J.-H., Betarbet, R., & Greenamyre, J. T. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8072 · Cited by 708
Self-citationThe risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., & Richardson, R. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1346 · Cited by 639
Environmental risk factors and Parkinson's disease: A case‐control study in Taiwan
Liou, H. H., Tsai, M. C., Chen, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., & Chen, R. C. (1997) · Neurology · doi:10.1212/wnl.48.6.1583 · Cited by 616
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Occupational exposures to metals as risk factors for Parkinson's disease
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., & Richardson, R. J. (1997) · Neurology · doi:10.1212/wnl.48.3.650 · Cited by 476
Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats
Alam, M., & Schmidt, W. J. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00180-8 · Cited by 473
Animal models of neurological deficits: how relevant is the rat?
Cenci, M. A., Whishaw, I. Q., & Schallert, T. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn877 · Cited by 456
Janssen, A. J., Trijbels, F. J., Sengers, R. C., Smeitink, J. A., van den Heuvel, L. P., Wintjes, L. T., Stoltenborg-Hogenkamp, B. J., & Rodenburg, R. J. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.078873 · Cited by 373
Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease
Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P., Cargnin-Ferreira, E., Da Cunha, C., & Takahashi, R. N. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.035 · Cited by 343
Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J.-H., Lund, S., Na, H.-M., Taylor, G., Bence, N. F., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.003 · Cited by 342
Self-citationParkinson's disease: A test of the multifactorial etiologic hypothesis
Semchuk, K. M., Love, E. J., & Lee, R. G. (1993) · Neurology · doi:10.1212/wnl.43.6.1173 · Cited by 275
Fall, P.-A., Fredrikson, M., Axelson, O., & Gran�rus, A.-K. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1<28::aid-mds1007>3.0.co;2-o · Cited by 244
FLEMING, S. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.023 · Cited by 230
Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity
Gash, D. M., Rutland, K., Hudson, N. L., Sullivan, P. G., Bing, G., Cass, W. A., Pandya, J. D., Liu, M., Choi, D., Hunter, R. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21288 · Cited by 222
Compulsive, Abnormal Walking Caused by Anticholinergics in Akinetic, 6-Hydroxydopamine-Treated Rats
Schallert, T., Whishaw, I. Q., Ramirez, V. D., & Teitelbaum, P. (1978) · Science · doi:10.1126/science.564552 · Cited by 161
Schallert, T., & Tillerson, J. L. (2000) · Central Nervous System Diseases · doi:10.1007/978-1-59259-691-1_8 · Cited by 159
l-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats
Alam, M., & Schmidt, W. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.12.021 · Cited by 118
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat
Sakai, K., & Gash, D. M. (1994) · Brain Research · doi:10.1016/0006-8993(94)91533-4 · Cited by 82
Woodlee, M. T., Kane, J. R., Chang, J., Cormack, L. K., & Schallert, T. J. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.02.024 · Cited by 72
Fleming, S. M., Delville, Y., & Schallert, T. J. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.05.024 · Cited by 68
High prevalence of parkinsonism after occupational exposure to lead‐sulfate batteries
Kuhn, W., van Winkel, R., Woitalla, D., et al. (1998) · Neurology · doi:10.1212/wnl.50.6.1885 · Cited by 56
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice
Rojo, A. I., Montero, C., Salazar‐Roa, M., Close, R. M., Fernández‐Ruíz, J., Sánchez-González, M. Á., de Sagarra, M. R., Jackson-Lewis, V. R., Cavada, C., & Cuadrado, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05060.x · Cited by 54
Ohashi, S., Mori, A., Kurihara, N., Mitsumoto, Y., & Nakai, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.017 · Cited by 49
A rat model of Parkinsonism shows depletion of dopamine in the retina
Biehlmaier, O., Alam, M., & Schmidt, W. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.08.001 · Cited by 41
Clinical and pathological features in hydrocarbon‐induced Parkinsonism
Pezzoli, G., Strada, O., Silani, V., Zecchinelli, A., Perbellini, L., Javoy-Agid, F., Ghidoni, P., Motti, E., Masini, T., Scarlato, G., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400616 · Cited by 40
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model
Cannon, J. R., Keep, R. F., Hua, Y., Richardson, R. J., Schallert, T. J., & Xi, G. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.089 · Cited by 36
Self-citationHypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat
JOLICOEUR, F. B., Rivest, R., & Drumheller, A. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90245-f · Cited by 33
The role of environmental agents in Parkinson's disease
Monte, D. A. D. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00020-2 · Cited by 32
Cannon, J. R., Keep, R. F., Schallert, T. J., Hua, Y., Richardson, R. J., & Xi, G. (2006) · Brain Research · doi:10.1016/j.brainres.2006.07.094 · Cited by 31
Self-citationCentral nervous system diseases : innovative animal models from lab to clinic
Emerich, D. F., Dean, R. L., & Sanberg, P. R. (2000) · Humana Press eBooks · Cited by 27
Neuroprotection in Parkinson's disease: and now for something completely different?
Lang, A. E. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70605-6 · Cited by 23
Cited by
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Chin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 707
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Self-citationLiu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556
Metadata
- Authors
- Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 34
- Issue
- 2
- Pages
- 279-290
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2029503022
- Cited by
- 795
- References
- 36
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.